最新ニュース Bruker (NASDAQ:BRKR) 株価情報

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Bruker Corp

Guggenheim analyst Subbu Nambi reiterates Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Buy.

News

Reiteration

Analyst Ratings

BRKR

Guggenheim Reiterates Buy on Brukerto Buy

A. Preview of timsTOF Ultra 2 system with novel Athena Ion Processor (AIP):
- Improves protein group identification in single-cell proteomics (SCP) by 15%-20%, and peptide identifications in SCP by 20%-25%
-Advances immunopeptidomics with 15%-20% more immunopeptide identifications
B. Launch of DeutEx&#x2122; software for hydrogen-deuterium exchange (HDX-MS) analysis
C. OmniScape&#x2122; 2025b: a breakthrough in top-down protein sequencing software
D. Advances in ProteoScape&#x2122; and Glycoproteomics software capabilities
E. Advances in TwinScape&#x2122; for cloud-based, AI-enabled proteomics quality monitoring

Bruker Unveils 4D-Proteomics Breakthrough At US HUPO: Enhanced Single-Cell and Immunopeptidomics With timsTOF Ultra 2 And Athena Ion Processor

Stifel analyst Daniel Arias maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $70 to $57.

Price Target

Stifel Maintains Hold on Bruker, Lowers Price Target to $57

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $65 to $60.

Barclays Maintains Overweight on Bruker, Lowers Price Target to $60

Fiscal Year 2025 Financial Outlook
Bruker expects FY 2025 revenues of $3.47 to $3.54 billion, compared to FY 2024 revenues of $3.37 billion, with 3% to 5% year-over-year reported revenue growth, including:
<ul>
<li>CER revenue growth of 5% to 7%</li>
<li>Organic revenue growth of 3% to 4%</li>
<li>M&amp;A revenue growth contribution of 2% to 3%</li>
<li>Foreign currency translation headwind of approximately 2%</li>
</ul>
Bruker expects FY 2025 non-GAAP EPS of $2.67 to $2.72, compared to FY 2024 non-GAAP EPS of $2.41, an increase of 11% to 13% year-over-year, with CER non-GAAP EPS growth of 14% to 16%.
Bruker's FY 2025 revenue and non-GAAP EPS guidance is based on foreign currency exchange rates as of December 31, 2024.

Guidance

Bruker FY2025 Outlook: Adj EPS $2.67-$2.72 vs $2.67 Estimate; Sales $3.470B-$3.540B vs $3.57B Estimate

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.74 by 2.7 percent. This is a 8.57 percent increase over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $979.60 million which beat the analyst consensus estimate of $966.35 million by 1.37 percent. This is a 14.64 percent increase over sales of $854.50 million the same period last year.

Earnings

Earnings Beats

Bruker Q4 2024 Adj EPS $0.76 Beats $0.74 Estimate, Sales $979.60M Beat $966.35M Estimate

ABNB

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

In the preceding three months, 5 analysts have released ratings for Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Bruker, presenting an average target of $68.6, a high estimate of $80.00, and a low estimate of $60.00. Experiencing a 11.2% decline, the current average is now lower than the previous average price target of $77.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739221242_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bruker's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Bruker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>Get to Know Bruker Better</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>Financial Milestones: Bruker's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Bruker's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.37% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Bruker's net margin is impressive, surpassing industry averages. With a net margin of 4.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bruker's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.27% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Bruker's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.68%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.34, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bruker Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

WIIM

Bruker shares are trading lower after Barclays cut its price target on the stock from $69 to $65.

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $69 to $65.

Barclays Maintains Overweight on Bruker, Lowers Price Target to $65

Bruker Expects Q4 2024 Revenue Between $970M-$980M; Projects 2025 Constant Exchange Rate Revenue Growth In Upper Mid-Single Digits

"We respectfully disagree with the District Court's decision to grant an injunction with respect to sales of GeoMx products to new customers in the United States and we expect to promptly seek a stay of any injunction that is finally ordered," said Todd Garland, President of the Bruker Spatial Biology division. "We also look forward to the appeal of our case being heard by the U.S. Court of Appeals for the Federal Circuit, a court that specializes in patent disputes. We remain steadfast in our view that the patents that were licensed by 10x and asserted against us are invalid and describe a fundamentally different method than what is used by the GeoMx system. We strongly believe that we should be vindicated on appeal. Bruker remains dedicated to ensuring that the scientific community has the freedom to select the best spatial biology platforms to advance their research."

Management

Bruker Comments On Delaware District Court's Post-Trial Ruling In Case Involving GeoMx Digital Spatial Profiler Products; Says  "We Look Forward To The Appeal Of Our Case Being Heard By The U.S. Court Of Appeals For The Federal Circuit... We Strongly Believe That We Should Be Vindicated On Appeal."

Legal

Reported Earlier, Delaware Jury Awards 10x Genomics $31.7M In Patent Case Against NanoString; Permanent Injunction On GeoMx Takes Effect January 10, 2025, With Royalties For Existing Installations; Additional Rulings On CosMx Expected Spring 2025

The instrument, located at the University of Zürich, is the second 1.2 GHz NMR in Switzerland, with the first at ETH used for developing solid-state NMR techniques, and studying materials and biological systems.

Bruker Reveals 1.2 GHz NMR Spectrometer At Swiss High-field NMR Facility

Guggenheim analyst Subbu Nambi initiates coverage on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy rating and announces Price Target of $72.

Initiation

Guggenheim Initiates Coverage On Bruker with Buy Rating, Announces Price Target of $72

B of A Securities analyst Derik De Bruin maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and raises the price target from $78 to $80.

B of A Securities Maintains Buy on Bruker, Raises Price Target to $80

Analysts' ratings for Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $70.0, a high estimate of $75.00, and a low estimate of $60.00. Highlighting a 10.06% decrease, the current average has fallen from the previous average price target of $77.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1733864514_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bruker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Terence Malone</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Terence Malone</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$75.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bruker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bruker's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bruker's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>Unveiling the Story Behind Bruker</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>A Deep Dive into Bruker's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Bruker showcased positive performance, achieving a revenue growth rate of 16.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Bruker's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.27%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Bruker's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.68%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Bruker's debt-to-equity ratio surpasses industry norms, standing at 1.34. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bruker Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Arun Jayaram upgraded ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) from Neutral to Overweight and raised the price target from $120 to $123. ConocoPhillips shares closed at $103.51 on Wednesday. <a href="https://www.benzinga.com/quote/COP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Matthew Sykes upgraded the rating for Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Sell to Neutral and maintained the price target of $60. Bruker shares closed at $59.50 on Wednesday. <a href="https://www.benzinga.com/quote/BRKR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley analyst Meta Marshall upgraded Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) from Equal-Weight to Overweight and raised the price target from $23 to $28. Hewlett Packard shares closed at $21.76 on Wednesday. <a href="https://www.benzinga.com/quote/HPE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Emmanuel Rosner upgraded the rating for Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Peer Perform to Outperform. Mobileye Global shares closed at $17.08 on Wednesday. <a href="https://www.benzinga.com/quote/MBLY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Peter Weed upgraded Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Market Perform to Outperform and boosted the price target from $123 to $129. Okta shares closed at $86.11 on Wednesday. <a href="https://www.benzinga.com/quote/OKTA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying COP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49-1024x563.png" alt="" class="wp-image-678536" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42332881/dow-settles-above-45000-for-first-time-investor-sentiment-improves-fear-greed-index-in-greed-zone">Dow Settles Above 45,000 For First Time As Salesforce, Marvell Surge: Investor Sentiment Improves, Fear Index In &#8216;Greed&#8217; Zone</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

MBLY

OKTA

This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Goldman Sachs analyst Matthew Sykes upgrades Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Sell to Neutral and maintains the price target from $60 to $60.

Goldman Sachs Upgrades Bruker to Neutral, Maintains Price Target to $60

Press Releases

Bruker Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research

Bruker Announces Date and Time of Fourth Quarter 2024 Earnings Release and Webcast

Bruker Reports Fourth Quarter and Full Year 2024 Financial Results

Bruker Corporation to Present at Upcoming Investor Conferences

Bruker Announces Quarterly Dividend

Bruker Appoints Laura Francis to its Board of Directors

Bruker Spatial Biology to Announce Groundbreaking Advances at AGBT 2025

Bruker Advances Single-Cell Proteomics and Immunopeptidomics Performance; Unveils New Proteomics Software and Applications for Enhanced Biological Insights at US HUPO

Bruker Launches X4 POSEIDON™ Advanced X-Ray Microscope for Three-Dimensional Microscopy in Industrial and Scientific Applications

PGNY

SIBN

SWAV

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Bruker

ニュース

最新ニュース Bruker (NASDAQ:BRKR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル